Hirudin for Improvement of Thrombolysis - HIT-III


The HIT-III trial was a prospective, randomized, double-blind multicenter trial designed to compare a recombinant hirudin (HBW 023) with heparin as adjuncts to thrombolysis in patients with acute myocardial infarction and to investigate the safety of hirudin therapy and its effects on mortality, reinfarction, and major bleeding.